Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$0.86

-0.03 (-3.38%)

12:36
07/10/18
07/10
12:36
07/10/18
12:36

Federated Investors reports 14.7% passive stake in Catabasis Pharmaceuticals

CATB Catabasis Pharmaceuticals
$0.86

-0.03 (-3.38%)

08/14/17
OPCO
08/14/17
NO CHANGE
Target $4
OPCO
Outperform
Catabasis Pharmaceuticals price target lowered to $4 from $9 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Catabasis Pharmaceuticals to $4 from $9 as a comprehensive Phase 3 program potentially pushes out sales timelines and reduces sales potential. The analyst reiterates an Outperform rating on the shares.
09/29/17
SBSH
09/29/17
NO CHANGE
Target $1.5
SBSH
Neutral
PTC panel vote not favorable for Catabasis despite share rally, says Citi
Catabasis Pharmaceuticals (CATB) shares traded 22% higher yesterday as an FDA panel considered the approval of PTC Therapeutics' (PTCT) Duchenne muscular dystrophy agent Translarna, Citi analyst Joel Beatty tells investors in a research note. The general tone of FDA comments support the view that the agency is willing to be flexible with regards to accepting a variety of outcomes as approvable endpoints in DMD, as long as they are prospectively defined, Beatty contends. The analyst, however, thinks Catabasis' edasalonexent and Translarna would likely be used synergistically and would not be competitors. As such, he does not see the negative vote at yesterday's panel meeting as being favorable for Catabasis. Beatty keeps a Neutral rating on Catabasis shares with a $1.50 price target. The stock closed yesterday up 22%, or 40c, to $2.23.
10/05/17
OPCO
10/05/17
NO CHANGE
Target $7
OPCO
Outperform
Catabasis Pharmaceuticals price target raised to $7 from $4 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Catabasis Pharmaceuticals to $7 from $4 after the company reported positive 36-week data from the ongoing Part C open label extension of its Phase 2 MoveDMD clinical trial in Duchenne muscular dystrophy. The analyst reiterates an Outperform rating on the shares.
11/20/17
SBSH
11/20/17
UPGRADE
Target $2.5
SBSH
Buy
Catabasis Pharmaceuticals upgraded to Buy from Neutral at Citi
Citi analyst Joel Beatty upgraded Catabasis Pharmaceuticals to Buy while lowering his price target for the shares to $2.50 from $3.50. Non-dilutive funding is possible for the Phase 3 trial given its low cost, which could provide upside to the current share price, Beatty tells investors in a research note. He believes the extension study data in Q1 of 2018 could help attract some non-dilutive financing.

TODAY'S FREE FLY STORIES

KLXE

KLX Energy

$32.22

0.27 (0.85%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Conference/Events
KLX Energy to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MCD

McDonald's

$167.45

0.61 (0.37%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Recommendations
McDonald's analyst commentary  »

McDonald's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HON

Honeywell

$153.49

-1.73 (-1.11%)

08:02
10/22/18
10/22
08:02
10/22/18
08:02
Recommendations
Honeywell analyst commentary  »

Honeywell growth and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROW

Arrow Financial

$34.92

-0.39 (-1.10%)

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Earnings
Arrow Financial reports Q3 EPS 64c, one estimate 65c »

Reports Q3 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$158.35

2.15 (1.38%)

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Hot Stocks
Accenture agrees to acquire New Content, terms not disclosed »

Accenture has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 13

    Nov

MCRB

Seres Therapeutics

08:01
10/22/18
10/22
08:01
10/22/18
08:01
Initiation
Seres Therapeutics initiated  »

Seres Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLF

Cleveland-Cliffs

$11.05

-0.425 (-3.71%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
Cleveland-Cliffs analyst commentary  »

Cleveland-Cliffs dividend…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$77.74

-9.33 (-10.72%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
VF Corp. analyst commentary  »

VF Corp. near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Recommendations
Dynavax analyst commentary  »

Dynavax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LII

Lennox

$192.83

-3.91 (-1.99%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Earnings
Lennox reports Q3 adjusted EPS $2.72, consensus $2.92 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

YNDX

Yandex

$27.42

-2.07 (-7.02%)

08:00
10/22/18
10/22
08:00
10/22/18
08:00
Options
Yandex put buyer realizes 65% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ENIA

Enel Americas

$7.73

0.01 (0.13%)

07:59
10/22/18
10/22
07:59
10/22/18
07:59
Initiation
Enel Americas initiated  »

Morgan Stanley resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$26.78

-0.16 (-0.59%)

, SVU

Supervalu

$32.50

0.01 (0.03%)

07:57
10/22/18
10/22
07:57
10/22/18
07:57
Recommendations
United Natural Foods, Supervalu analyst commentary  »

United Natural Foods…

UNFI

United Natural Foods

$26.78

-0.16 (-0.59%)

SVU

Supervalu

$32.50

0.01 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SU

Suncor

$35.73

0.24 (0.68%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Upgrade
Suncor rating change  »

Suncor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

VIOT

Viomi Technology

$8.11

-0.21 (-2.52%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Initiation
Viomi Technology initiated  »

Viomi Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Hot Stocks
Mirati Therapeutics provides sitravatinib update after meeting with FDA »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JTPY

JetPay

$2.07

(0.00%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Hot Stocks
Breaking Hot Stocks news story on JetPay »

JetPay trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

07:55
10/22/18
10/22
07:55
10/22/18
07:55
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

07:54
10/22/18
10/22
07:54
10/22/18
07:54
Recommendations
Fiat Chrysler analyst commentary  »

Fiat Chrysler sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

EWZ

MSCI Brazil Index

$38.92

0.31 (0.80%)

07:54
10/22/18
10/22
07:54
10/22/18
07:54
Technical Analysis
MSCI Brazil Index: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CJREF

Corus Entertainment

$0.00

(0.00%)

07:53
10/22/18
10/22
07:53
10/22/18
07:53
Upgrade
Corus Entertainment rating change  »

Corus Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTHM

Livent

$16.35

(0.00%)

07:53
10/22/18
10/22
07:53
10/22/18
07:53
Initiation
Livent initiated  »

Livent initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACRX

AcelRx

$3.62

-0.53 (-12.77%)

07:52
10/22/18
10/22
07:52
10/22/18
07:52
Recommendations
AcelRx analyst commentary  »

AcelRx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

EEM

iShares MSCI Emerging Markets ETF

$39.69

0.37 (0.94%)

07:52
10/22/18
10/22
07:52
10/22/18
07:52
Technical Analysis
iShares MSCI Emerging Markets ETF: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.